219 related articles for article (PubMed ID: 24675175)
1. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
Kuppast B; Spyridaki K; Liapakis G; Fahmy H
Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of new thiazolo[4,5-d]pyrimidines as Corticotropin releasing factor modulators.
Kuppast B; Spyridaki K; Lynch C; Hu Y; Liapakis G; Davies GE; Fahmy H
Med Chem; 2014; 11(1):50-9. PubMed ID: 25059547
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.
Teleb M; Kuppast B; Spyridaki K; Liapakis G; Fahmy H
Eur J Med Chem; 2017 Sep; 138():900-908. PubMed ID: 28750312
[TBL] [Abstract][Full Text] [Related]
4. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
McCarthy JR; Heinrichs SC; Grigoriadis DE
Curr Pharm Des; 1999 May; 5(5):289-315. PubMed ID: 10213797
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, structural optimization, SAR, in silico prediction of physicochemical properties and pharmacological evaluation of novel & potent thiazolo[4,5-d]pyrimidine corticotropin releasing factor (CRF) receptor antagonists.
Islam MR; Teleb M; Karageorgos V; Sakellaris S; Papadopoulos M; Pirmettis I; Fronczek FR; Liapakis G; Fahmy H
Eur J Pharm Sci; 2022 Feb; 169():106084. PubMed ID: 34856350
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
7. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
8. Don't stress about CRF: assessing the translational failures of CRF
Spierling SR; Zorrilla EP
Psychopharmacology (Berl); 2017 May; 234(9-10):1467-1481. PubMed ID: 28265716
[TBL] [Abstract][Full Text] [Related]
9. Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats.
Lelas S; Wong H; Li YW; Heman KL; Ward KA; Zeller KL; Sieracki KK; Polino JL; Godonis HE; Ren SX; Yan XX; Arneric SP; Robertson DW; Hartig PR; Grossman S; Trainor GL; Taub RA; Zaczek R; Gilligan PJ; McElroy JF
J Pharmacol Exp Ther; 2004 Apr; 309(1):293-302. PubMed ID: 14742750
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
Saito T; Obitsu T; Minamoto C; Sugiura T; Matsumura N; Ueno S; Kishi A; Katsumata S; Nakai H; Toda M
Bioorg Med Chem; 2011 Oct; 19(20):5955-66. PubMed ID: 21930387
[TBL] [Abstract][Full Text] [Related]
11. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
Gannon RL; Millan MJ
Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
[TBL] [Abstract][Full Text] [Related]
13. Selective antagonism of CRF1 receptor by a substituted pyrimidine.
Sakellaris S; Matsoukas MT; Karageorgos V; Poulaki S; Kuppast B; Margioris A; Venihaki M; Fahmy H; Liapakis G
Hormones (Athens); 2019 Jun; 18(2):215-221. PubMed ID: 30980254
[TBL] [Abstract][Full Text] [Related]
14. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
Saito T; Obitsu T; Kondo T; Matsui T; Nagao Y; Kusumi K; Matsumura N; Ueno S; Kishi A; Katsumata S; Kagamiishi Y; Nakai H; Toda M
Bioorg Med Chem; 2011 Sep; 19(18):5432-45. PubMed ID: 21865047
[TBL] [Abstract][Full Text] [Related]
15. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
Fahmy H; Kuppast B; Ismail MT
Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
[TBL] [Abstract][Full Text] [Related]
17. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats.
Greenwood-Van Meerveld B; Johnson AC; Cochrane S; Schulkin J; Myers DA
Neurogastroenterol Motil; 2005 Jun; 17(3):415-22. PubMed ID: 15916629
[TBL] [Abstract][Full Text] [Related]
18. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
19. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome.
Taché Y; Martinez V; Million M; Maillot C
Eur J Surg Suppl; 2002; (587):16-22. PubMed ID: 16144197
[TBL] [Abstract][Full Text] [Related]
20. Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
Gehlert DR; Shekhar A; Morin SM; Hipskind PA; Zink C; Gackenheimer SL; Shaw J; Fitz SD; Sajdyk TJ
Eur J Pharmacol; 2005 Feb; 509(2-3):145-53. PubMed ID: 15733549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
